Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger
On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. &…
2 years ago
Wire Stories
Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2023
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO:6594) (OTC US:NJDCY) today announced its consolidated financial results under the…
2 years ago
Nidec Announces Differences between Projected and Actual Financial Results for First-Half FY2023
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Companyâ€) today announced differences between…
2 years ago
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed…
2 years ago
Bias in AI Computer Vision Systems Dramatically Reduced with Synthetic Data ‘Digital Humans’
Mindtech’s Digital DNA technology creates a diverse range of Digital Humans that allow for statistically…
2 years ago
APO’s Newest Member Turkiye Hosts 64th Workshop Meeting of Heads of National Productivity Organizations
ANKARA, Turkiye--(BUSINESS WIRE)--#APO--Turkiye, the Asian Productivity Organization’s (APO’s) newest member, generously hosted the 64th Workshop…
2 years ago
Covation Holdings Continues Expansion in Asia Pacific With New Regional Corporate Headquarters
HONG KONG--(BUSINESS WIRE)--Covation Holdings Limited, the global manufacturer of multiple wheeled goods brands, today announced…
2 years ago
Berkshire Hathaway Specialty Insurance Names Sami Jaghbir as Underwriting Manager in Queensland
BRISBANE, Australia & BOSTON--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has appointed…
2 years ago
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus…
2 years ago
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
Encouraging overall response rate of 46% and disease control rate of 98% with a median…
2 years ago